Amgen | AMGN

Stock Price
336.70
Daily Change
0.22 0.07%
Monthly
-2.76%
Yearly
16.84%
Q2 Forecast
332.41

EPS Reference Time Actual Consensus Previous
2026-04-30 FY2026Q1 PM 5.15 4.79 4.90
2026-02-03 FY2025Q4 PM 5.29 4.72 5.31
2025-11-04 FY2025Q3 PM 5.64 5.07 5.58
2025-08-05 FY2025Q2 PM 6.02 5.23 4.97
2025-05-01 FY2025Q1 PM 4.90 4.73 3.96



Peers Price Chg Day Year Date
Takeda 5,118.00 -2.00 -0.04% 18.64% May/29
AbbVie 217.60 -1.03 -0.47% 16.92% May/29
Agios Pharmaceuticals 29.40 -1.02 -3.35% -8.38% May/29
ALKERMES 42.19 2.25 5.63% 37.83% May/29
Amgen 336.70 0.22 0.07% 16.84% May/29
Biogen 196.01 -0.38 -0.19% 51.02% May/29
BioMarin Pharmaceutical 57.31 4.57 8.67% -1.31% May/29
Bristol-Myers Squibb 57.18 0.27 0.47% 18.43% May/29
Coherus Biosciences 1.60 -0.06 -3.33% 104.75% May/29
Exelixis 50.49 -0.96 -1.87% 17.31% May/29

Indexes Price Day Year Date
US500 7580 16.43 0.22% 28.22% May/29
USND 26973 55.15 0.20% 41.12% May/29
US30 51032 363.49 0.72% 20.73% May/29
US100 30333 109.29 0.36% 42.14% May/29

Amgen traded at $336.70 this Friday May 29th, increasing $0.22 or 0.07 percent since the previous trading session. Looking back, over the last four weeks, Amgen gained 2.76 percent. Over the last 12 months, its price rose by 16.84 percent. Looking ahead, we forecast Amgen to be priced at 332.41 by the end of this quarter and at 312.58 in one year, according to Trading Economics global macro models projections and analysts expectations.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.



News Stream
Amgen Stock Price Hits 14-week Low
Amgen shares decreased to 334.00 USD, the lowest since January 2026. Over the past 4 weeks, Amgen lost 3.77%, and in the last 12 months, it increased 16.38%.
2026-04-29
Amgen Stock Price Hits 8-week Low
Amgen shares decreased to 344.54 USD, the lowest since February 2026. Over the past 4 weeks, Amgen lost 8.24%, and in the last 12 months, it increased 19.41%.
2026-04-06
Amgen Stock Price Hits 4-week Low
Amgen shares decreased to 361.38 USD, the lowest since February 2026. Over the past 4 weeks, Amgen lost 4.79%, and in the last 12 months, it increased 13.46%.
2026-03-17